Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid

Digestive and Liver Disease

Volumn 35, Issue 5, 2003, Pages 306-308

  Chapman, R W ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; PLACEBO; PREDNISOLONE; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

APOPTOSIS; BALLOON DILATATION; BILE DUCT OBSTRUCTION; BILE FLOW; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENDOSCOPIC THERAPY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER PROTECTION; LIVER TRANSPLANTATION; NOTE; PRIMARY SCLEROSING CHOLANGITIS; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; SCLEROSING CHOLANGITIS;

CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; HUMANS; URSODEOXYCHOLIC ACID;

EID: 0142119485     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00072-0     Document Type: Review

References (16)

1. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver diseases. Hepatology 2002;36:525-31.
2. Martinez JD, Stratagoules ED, La Rue JM, Powell AA, Gause PR. Different bile acids exhibit distinct biological effects. Nutr Cancer 1998;31:111-8.
3. Tung BY, Edmond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonie neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
4. Wolf JM, Rybicki L, Lashner BA. Ursodeoxycholic acid is not chemoprotective for colorectal cancer in ulcerative colitis patients with primary sclerosing cholangitis (abstract). Gastroenterology 2001;121:2276.
5. O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 1991;14:838.
6. Beuers U, Spengler U, Kruis W, Aydemir C, Wiebecke B, Pape GR, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-14.
7. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofman WI, Theilmann I. Effect of Ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
8. Lindor KD. The Mayo PSC/UDCA Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-5.
9. Okolicsanyi L, Groppo M, Floreani A, Morselli-Labate AM, Rusticali AG, Battocchia A, et al. Medical treatment with low-dose UDCA in primary sclerosing cholangitis (PSC): results of a retrospective Italian multicentre survey. Dig Liver Dis 2003;35:325-31.
10. Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995;23:283-9.
11. Hirano F, Tanaka H, Makino Y, Okamoto K, Makino I. Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression. J Gastoenterol 1996;31:55.
12. Mitchell SA, Bansi DS, Hunt N, von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastoenterology 2001;:122.
13. Harnois DM, Angulo P, Jorgensen RA, La Russo NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Amer J Gastroenterol 2001;96:1558-66.
14. Schramm C, Schirmacher P, Helmreich-Becker I, Manns M. Combined therapy with azathioprine prednisolone and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999;131:94-946.
15. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S. Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8 years prospective study. J Hepatol 1997;26:56-61.
16. Gow PJ, Chapman RW Liver transplantation for primary sclerosing cholangitis. Liver 2000;20:97-103.